10-Q: Atossa Therapeutics Reports Third Quarter 2024 Financial Results and Provides Clinical Program Update

Atossa Therapeutics reported a net loss of $7.2 million for the third quarter of 2024, while highlighting positive preliminary data from its (Z)-endoxifen breast density study.

Summary

• Atossa Therapeutics reported a net loss of $7.2 million for the three months ended September 30, 2024, and a net loss of $19.2 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents totaled $74.8 million as of September 30, 2024, with a working capital of $71.3 million.
• Research and development expenses decreased to $3.4 million for the quarter and $10.7 million for the nine months ended September 30, 2024, compared to $4.5 million and $11.7 million for the same periods in 2023, respectively.
• General and administrative expenses were $3.0 million for the quarter and $9.8 million for the nine months ended September 30, 2024, compared to $3.0 million and $10.7 million for the same periods in 2023, respectively.
• The company recorded an impairment charge of $1.7 million on its investment in equity securities for both the three and nine months ended September 30, 2024.
• Atossa has not generated revenue and expects to continue incurring losses as it develops its pharmaceutical programs.
• The company believes its current cash will fund operations for at least one year from the date of the financial statements.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive clinical trial results and a strong cash position, the company is still incurring significant losses and needs to raise additional capital. The sentiment is neutral to slightly negative due to the ongoing losses and need for future funding.

Positives

• The company has a strong cash position of $74.8 million.
• Preliminary data from the Karisma study showed significant reductions in mammographic breast density with (Z)-endoxifen.
• Multiple clinical trials for (Z)-endoxifen are progressing, including studies for breast density, DCIS, and neoadjuvant treatment.
• The company has received authorization from the U.S. FDA for its Investigational New Drug (IND) application for oral (Z)-endoxifen.
• The company has a share repurchase program authorized by the board of directors.

Negatives

• The company reported a net loss of $7.2 million for the third quarter of 2024 and $19.2 million for the nine months ended September 30, 2024.
• The company has incurred net losses and negative operating cash flows since inception.
• The company recorded a $1.7 million impairment charge on its investment in equity securities.
• The company has not established an ongoing source of revenue sufficient to cover its operating costs.
• The company is dependent on third-party service providers for critical operational activities.

Risks

• The company needs to raise substantial additional capital to fund its operations.
• Clinical trials may not demonstrate the efficacy and safety of product candidates.
• The company is subject to regulatory risks and may not obtain necessary approvals.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company is subject to intellectual property risks and may not be able to protect its proprietary technology.
• The company is dependent on third-party service providers for critical operational activities.
• The company's stock price is volatile and may be affected by various factors.
• The company may experience delays in clinical trials or may not be able to conduct trials in a timely manner.
• The company may be subject to product liability claims.
• The company may be unable to maintain compliance with Nasdaq listing standards.

Future Outlook

The company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity offerings, debt financings or other sources, including potential corporate collaborations, licenses and other similar arrangements. Management believes its currently available cash and cash equivalents will be sufficient to finance the company's operations for at least one year from the date these Condensed Consolidated Financial Statements are issued.

Management Comments

• Management believes its currently available cash and cash equivalents will be sufficient to finance the company's operations for at least one year from the date these Condensed Consolidated Financial Statements are issued.
• The company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity offerings, debt financings or other sources, including potential corporate collaborations, licenses and other similar arrangements.

Industry Context

Atossa is operating in the competitive biopharmaceutical industry, focusing on breast cancer treatments. The company's (Z)-endoxifen program is aimed at addressing unmet needs in breast cancer prevention and treatment, including reducing mammographic breast density and treating ER+/HER2breast cancer. The company is also exploring the use of AI in its drug discovery efforts.

Comparison to Industry Standards

• Atossa's cash burn rate of approximately $14 million for the nine months ended September 30, 2024, is typical for a clinical-stage biopharmaceutical company.
• The company's focus on (Z)-endoxifen, a metabolite of tamoxifen, is a unique approach compared to other companies developing novel breast cancer therapies.
• The reported 19.3% and 26.5% reduction in mammographic breast density in the Karisma study is a significant result compared to other studies in the field.
• The company's multiple Phase 2 trials for (Z)-endoxifen are in line with industry standards for clinical development of new drugs.
• The company's collaboration with Quantum Leap Healthcare Collaborative (QLHC) and the I-SPY 2 trial is a common approach for smaller biopharmaceutical companies to accelerate clinical development.

Management Changes

Corporate Governance

Legal Proceedings

• Intas Pharmaceuticals LTD. filed a Petition for Post Grant Review (PGR) with the U.S. Patent and Trademark Office seeking to invalidate one of the company's issued patents.
• The company is actively contesting the PGR Petition and believes that the Patent was properly granted and is valid and enforceable.
• The Indian Pharmaceutical Alliance filed a Pre-Grant Opposition against one of the company's pending Indian patent applications.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may benefit from the company's stock-based compensation plans.
• Patients may benefit from the development of new treatments for breast cancer.
• The company's suppliers and service providers may benefit from the company's ongoing operations and clinical trials.

Next Steps

• The company expects to initiate the Treatment Cohort of the EVANGELINE study in the fourth quarter of 2024.
• The company will continue to enroll patients in the ongoing clinical trials for (Z)-endoxifen.
• The company will continue to evaluate the data from the Karisma study and other clinical trials.
• The company will continue to seek additional funding to support its operations and clinical development programs.

Key Dates

Keywords

Atossa Therapeutics, Z-endoxifen, breast cancer, mammographic breast density, clinical trials, neoadjuvant treatment, ER+ breast cancer, HER2breast cancer, biopharmaceutical, oncology